Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Squamous Cell Carcinoma of Head and Neck 24Head and Neck Neoplasms 21Lung Neoplasms 19Neoplasms 18Stomach Neoplasms 15Urinary Bladder Neoplasms 14Uterine Cervical Neoplasms 11Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Esophageal Neoplasms 11Colorectal Neoplasms 11Pancreatic Neoplasms 10Biliary Tract Neoplasms 10Carcinoma, Transitional Cell 9Triple Negative Breast Neoplasms 8Neoplasm Metastasis 8Breast Neoplasms 8Oropharyngeal Neoplasms 7Mesothelioma, Malignant 7Melanoma 7Cholangiocarcinoma 7Carcinoma, Squamous Cell 6Recurrence 5Nasopharyngeal Carcinoma 5Mesothelioma 5Esophageal Squamous Cell Carcinoma 5Carcinoma 5Nasopharyngeal Neoplasms 4Mouth Neoplasms 4

Interventions

pembrolizumab 9avelumab 8Nivolumab 6Ipilimumab 4Radiotherapy 3durvalumab 2cemiplimab 2atezolizumab 2aldesleukin 2Specimen Handling 2Radiation 2Magnetic Resonance Spectroscopy 2Interferon-beta 2Cyclophosphamide 2Biopsy 2Bevacizumab 2tremelimumab 1sargramostim 1sapanisertib 1regorafenib 1prednylidene 1poly ICLC 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1lutetium Lu 177 dotatate 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1deltacortene 1decitabine and cedazuridine drug combination 1bempegaldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Merkel Cell × Cisplatin × Clear all
NCT03167164 2025-02-21

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡